Core Scientific, Inc. Tranche 2 Warrants
NASDAQ Global SelectTotal Valuation
Core Scientific, Inc. Tranche 2 Warrants carries a market capitalization of 5.77B, placing it among publicly traded companies globally. Its enterprise value stands at 10.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.77B |
| Enterprise Value | 10.49B |
Share Statistics
Core Scientific, Inc. Tranche 2 Warrants currently has 319.59M shares outstanding.
| Shares Outstanding | 319.59M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -3.29 |
| P/TBV Ratio | -3.01 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 23.82 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 5.23 |
Financial Position
Core Scientific, Inc. Tranche 2 Warrants maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -177.65, indicating conservative leverage, while an interest coverage ratio of -26.98 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.89 |
| Quick Ratio | 0.79 |
| Debt / Equity | -177.65 |
| Debt / EBITDA | -32.79 |
| Interest Coverage | -26.98 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.59 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -131.95 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Core Scientific, Inc. Tranche 2 Warrants has paid 2.73M in income taxes, reflecting an effective tax rate of 0.04.
| Income Tax | 2.73M |
| Effective Tax Rate | 0.04 |
Stock Price Statistics
Core Scientific, Inc. Tranche 2 Warrants's stock has gained approximately 28.05755% over the past 52 weeks. The 50-day moving average sits at 20.88, while the 200-day moving average is 19.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | 28.05755% |
| 50-Day Moving Average | 20.88 |
| 200-Day Moving Average | 19.68 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -131.06M, while operating income came in at -205.89M.
| Revenue | 440.31M |
| Gross Profit | 124.81M |
| Operating Income | -205.89M |
| Pretax Income | -1.43B |
| Net Income | -1.43B |
| EBITDA | -131.06M |
| EBIT | -205.89M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Core Scientific, Inc. Tranche 2 Warrants holds 1.77B in cash and equivalents against 4.30B in total debt, resulting in a net debt position of 2.53B. Total book value stands at -2.42B, with working capital of -294.15M providing operational flexibility.
| Cash & Cash Equivalents | 1.77B |
| Total Debt | 4.30B |
| Net Debt | 2.53B |
| Equity (Book Value) | -2.42B |
| Book Value Per Share | -7.57 |
| Working Capital | -294.15M |
Cash Flow
Core Scientific, Inc. Tranche 2 Warrants produced 515.80M in operating cash flow over the past twelve months.
| Operating Cash Flow | 515.80M |
| Capital Expenditures | -1.48B |
| Free Cash Flow | -967.97M |
| FCF Per Share | N/A |
Margins
Core Scientific, Inc. Tranche 2 Warrants operates with a gross margin of 28.35, reflecting its pricing power and cost economics. The operating margin of -46.76 and net profit margin of -325.31 provide insight into operational efficiency.
| Gross Margin | 28.35 |
| Operating Margin | -46.76 |
| Pretax Margin | -324.69 |
| Profit Margin | -325.31 |
| EBITDA Margin | -29.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -39.75 |
| FCF Yield | N/A |
Scores
Core Scientific, Inc. Tranche 2 Warrants posts an Altman Z-Score of -1.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.07 |